Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction - Pharmaceutical Technology

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk. The approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk. Mounjaro is the first GIP/GLP-1-targeting therapy to secure approval for cardiovascular risk reduction. Credit: MKPhoto12 / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Eli Lilly’s blockbuster type 2 diabetes therapy, Mounjaro (tirzepatide), as a treatment for cardiovascular risk reduction in patients with the cardiometabolic condition – expanding the drug’s label following its rise to become the top-selling prescription medication…

Source: Pharmaceutical Technology